Led by Manish Sagar, MD, an infectious diseases physician at BMC, HIV-1 virus characteristics were identified to predict treatment efficacy with a specific antibody treatment using sequence-based methods.Sagar identified a vaginal resident CD1a + classical dendritic cell population able to support CCR5-tropic but not CXCR4-tropic HIV-1 replication in vitro , suggesting that these cells might play an active role in the selection of transmitted viral variants during sexual HIV acquisition.
Events - Primer's event detection algorithm clusters and summarizes multiple documents describing real-world events.
Mentions - Mentions are snippets of text that map to a person.
Docs - The number of documents that match to a person in Primer's corpus of news articles.
Full tech explainer here.
Remember to check the sources and follow Wikipedia's guidelines.
The identified virus characteristics may be used to determine if a patient is a good or poor candidate for specific antibody-based treatments in the future, reducing time and cost involved in treating the virus. In the study, HIV-1 envelope sequence motifs were identified that predict treatment efficacy with a certain type of antibody treatment. These findings will allow physicians to make better-informed decisions on treatment plans for patients with HIV-1, ultimately treating the virus to slow it down earlier.
A list of HIV prevention clinical trials discussed at HIV Research for Prevention 2018 is presented in Table 1. Who is using PrEP? New ARVs and combination products for prevention Raphael Landovitz 1 provided a comprehensive overview of work to identify new systemic PrEP products, including oral tenofovir alafenamide /FTC, injectable cabotegravir, bNAbs, the DPV vaginal ring, implantable devices, and microneedle array patches. Multipurpose products, providing protection against HIV and pregnancy, will provide exciting new options for women.